BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

(2019) Rumani Singh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Recent advances in the development of Mcl-1 inhibitors for cancer therapy

(2019) Alexander W. Hird et al.   PHARMACOLOGY & THERAPEUTICS

The Coming Decade of Cell Death Research: Five Riddles

(2019) Douglas R. Green   CELL

Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer

(2019) Paul M. Nguyen et al.   CELL DEATH AND DIFFERENTIATION

BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals

(2019) Rahul Srivastava et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma

(2019) Mathilde Rikje Willemijn de Jong et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

B-cell lymphoma 2 ovarian killer suppresses testicular cancer cell malignant behavior, but plays a role in platinum resistance

(2018) Jian Chu et al.   ANTI-CANCER DRUGS

The rise of apoptosis: targeting apoptosis in hematologic malignancies

(2018) Rebecca Valentin et al.   BLOOD

Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance

(2018) Justin Kale et al.   EMBO REPORTS

Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members

(2018) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL

(2018) Kim R. Kampen et al.   LEUKEMIA

Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis

(2018) Janet H. Zheng et al.   Cell Reports

Targeting BCL-2 regulated apoptosis in cancer

(2018) Kirsteen J. Campbell et al.   Open Biology

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

(2018) Georgia Greaves et al.   CELL DEATH AND DIFFERENTIATION

On cell death in the intestinal epithelium and its impact on gut homeostasis

(2018) J. Magarian Blander   CURRENT OPINION IN GASTROENTEROLOGY

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

(2018) Nehal J. Lakhani et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

(2018) Ryan S. Soderquist et al.   Nature Communications

AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies

(2018) Sean Caenepeel et al.   Cancer Discovery

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma

(2017) Erika Moravcikova et al.   INTERNATIONAL JOURNAL OF CANCER

A molecular signature for anastasis, recovery from the brink of apoptotic cell death

(2017) Gongping Sun et al.   JOURNAL OF CELL BIOLOGY

Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency

(2017) Evangelos Giampazolias et al.   NATURE CELL BIOLOGY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

(2017) Joel D. Leverson et al.   Cancer Discovery

BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation

(2016) Fabien Llambi et al.   CELL

Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease

(2016) J. Magarian Blander   FEBS Journal

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

(2016) Katelyn L. O'Neill et al.   GENES & DEVELOPMENT

BCL-2 system analysis identifies high-risk colorectal cancer patients

(2016) Andreas U Lindner et al.   GUT

Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak

(2016) Stephanie Einsele-Scholz et al.   JOURNAL OF CELL SCIENCE

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade

(2016) Michelle M. Williams et al.   MOLECULAR CANCER RESEARCH

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

(2016) J Tong et al.   ONCOGENE

Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes

(2016) Vicente Andreu-Fernández et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BOK: Oddball of the BCL-2 Family

(2016) Elizabeth A. Brem et al.   TRENDS IN CELL BIOLOGY

Bcl-xL is an oncogenic driver in colorectal cancer

(2016) Anna-Lena Scherr et al.   Cell Death & Disease

Bcl-2 is a critical mediator of intestinal transformation

(2016) Maartje van der Heijden et al.   Nature Communications

Mito-priming as a method to engineer Bcl-2 addiction

(2016) Jonathan Lopez et al.   Nature Communications

CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo

(2016) Austin Xun Ding et al.   eLife

Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer

(2016) Stephanie Berger et al.   eLife

Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members

(2015) Joseph T. Opferman   FEBS Journal

BAD-mediated apoptotic pathway is associated with human cancer development

(2015) XIAOMANG B STICKLES et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer

(2015) Haichao Zhang et al.   Molecular Cancer

Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death

(2015) Gabriel Ichim et al.   MOLECULAR CELL

Caspase-3 Promotes Genetic Instability and Carcinogenesis

(2015) Xinjian Liu et al.   MOLECULAR CELL

An interconnected hierarchical model of cell death regulation by the BCL-2 family

(2015) Hui-Chen Chen et al.   NATURE CELL BIOLOGY

BCL-2 family member BOK promotes apoptosis in response to endoplasmic reticulum stress

(2015) Marcos A. Carpio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

(2014) S Colak et al.   CELL DEATH AND DIFFERENTIATION

Differential retrotranslocation of mitochondrial Bax and Bak

(2014) F. Todt et al.   EMBO JOURNAL

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

(2014) L. Bai et al.   EUROPEAN JOURNAL OF CANCER

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis

(2014) P. S. Winter et al.   Science Signaling

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL

(2014) Michael F. T. Koehler et al.   ACS Medicinal Chemistry Letters

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

(2014) T. N. Chonghaile et al.   Cancer Discovery

Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance

(2013) H. Dai et al.   CANCER RESEARCH

Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis

(2013) D Westphal et al.   CELL DEATH AND DIFFERENTIATION

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

(2013) F. Abulwerdi et al.   MOLECULAR CANCER THERAPEUTICS

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

(2013) Kristopher A. Sarosiek et al.   MOLECULAR CELL

Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming

(2013) Barbara Schellenberg et al.   MOLECULAR CELL

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Mitochondrial Regulation of Cell Death

(2013) S. W. G. Tait et al.   Cold Spring Harbor Perspectives in Biology

Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

(2012) K. C. Goldsmith et al.   CANCER RESEARCH

BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice

(2012) F Ke et al.   CELL DEATH AND DIFFERENTIATION

Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells

(2012) Hideko Akagi et al.   Gastric Cancer

c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells

(2011) J. C. Allen et al.   BLOOD

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

(2011) Frank Edlich et al.   CELL

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization

(2011) Haiming Dai et al.   JOURNAL OF CELL BIOLOGY

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737

(2011) Daniëlle A. E. Raats et al.   CELLULAR ONCOLOGY

Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells

(2010) Shengbing Huang et al.   Autophagy

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

(2010) Scott Ackler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation

(2010) C Maas et al.   CELL DEATH AND DIFFERENTIATION

Resistance to Caspase-Independent Cell Death Requires Persistence of Intact Mitochondria

(2010) Stephen W.G. Tait et al.   DEVELOPMENTAL CELL

BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak

(2010) Han Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review

(2009) Suzanne Hector et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

PUMA Suppresses Intestinal Tumorigenesis in Mice

(2009) W. Qiu et al.   CANCER RESEARCH

The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins

(2009) Delphine Mérino et al.   JOURNAL OF CELL BIOLOGY

Caspase-independent Mitochondrial Cell Death Results from Loss of Respiration, Not Cytotoxic Protein Release

(2009) Lydia Lartigue et al.   MOLECULAR BIOLOGY OF THE CELL

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma

(2008) Domenico Coppola et al.   CANCER

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers

(2008) F. A. Sinicrope et al.   CLINICAL CANCER RESEARCH

Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

(2008) K. Okumura et al.   CLINICAL CANCER RESEARCH

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

(2008) A. R. Shoemaker et al.   CLINICAL CANCER RESEARCH

Regulation of Bcl-2 Family Proteins by Posttranslational Modifications

(2008) Anthony Letai et al.   CURRENT MOLECULAR MEDICINE

Suppression of Apoptosis, Crypt Hyperplasia, and Altered Differentiation in the Colonic Epithelia of Bak-Null Mice

(2008) Carrie A. Duckworth et al.   GASTROENTEROLOGY

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

Significance of Bcl-xL in human colon carcinoma

(2008) You-Li Zhang et al.   WORLD JOURNAL OF GASTROENTEROLOGY